Development of a psoriasis-like eruption during treatment with mepolizumab: A case report
Mepolizumab is effective for treating eosinophilic granulomatosis with polyangiitis (EGPA), severe eosinophilic asthma (SEA), and chronic rhinosinusitis with nasal polyps (CRSwNP), but unexpected adverse events associated with anti-interleukin-5 (IL-5) monoclonal antibodies have not yet been fully characterized. Herein, we report the case of a 56-year-old woman who developed a psoriasis-like eruption ~18 months after starting subcutaneous mepolizumab (300 mg every 4 weeks) for EGPA, SEA, and CRSwNP. She had no personal or family history of psoriasis or atopic dermatitis. Small punctate erythematous lesions first appeared on the back, before gradually spreading to the trunk and extremities. Skin biopsy showed neutrophilic infiltration within the stratum corneum, focal hypogranulosis, dilated tortuous capillaries, and increased mitotic activity in the basal layer. Prominent regular elongation of the rete ridges was not evident. The overall clinicopathological findings supported a diagnosis of a psoriasis-like eruption, with no eosinophils being identified in either the epidermis or dermis. Topical treatment with calcipotriol and betamethasone, while mepolizumab was continued at the same dose, produced only temporary improvement followed by recurrence. The eruption improved following temporary mepolizumab discontinuation, but the patient’s asthma exacerbations recurred. The mepolizumab dose was therefore reduced to 100 mg every 4 weeks, and a potent topical corticosteroid was added. The eruption resolved within 3 months thereafter, without recurrence, and control of EGPA, SEA, and CRSwNP was maintained. Although the psoriasis-like eruption improved after mepolizumab dose reduction, the concurrent topical treatment intensification means this improvement cannot be attributed to the dose reduction alone.
Authors
- Ryo Yano
- Takuma Koga (ORCID: https://orcid.org/0000-0002-6437-3012)
- Kenji Tsumura (ORCID: https://orcid.org/0009-0004-1665-3046)
- Jun Sasaki (ORCID: https://orcid.org/0000-0001-8319-3407)
- Yo Kaku (ORCID: https://orcid.org/0000-0001-8375-5895)
- Tomoaki Hoshino (ORCID: https://orcid.org/0000-0002-0459-4913)
- Yoshihisa Tokunaga
- Shinjiro Kaieda (ORCID: https://orcid.org/0009-0001-9608-1970)
- Masanobu Matsuoka
- Tomotaka Kawayama (ORCID: https://orcid.org/0000-0002-9537-4229)
- Takashi Kinoshita (ORCID: https://orcid.org/0000-0003-3260-9884)
Institutions
- Kurume University (JP)
Publication Details
- Journal
- Modern Rheumatology Case Reports
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/mrcr/rxag111
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00